This article was originally published in The Gray Sheet
Firm announces plans to pursue "strategic alternatives" for its genetic testing, diagnostic products and pharmaceutical intermediates businesses. Management is exploring divestiture, spin-out or management buyout, Genzyme disclosed on May 6. Genzyme will also initiate a $2 billion stock buyback. The initiatives are designed to increase shareholder value, CEO Henri Termeer told analysts
You may also be interested in...
Genzyme's marginally profitable genetic testing service business is being sold to Laboratory Corporation of America for $925 million, the firms announced Sept. 13
Drug maker Sanofi-Aventis is signaling potential interest in Genzyme's molecular diagnostics business, suggesting that the unit could be retained if Sanofi succeeds in its quest to acquire Genzyme
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.